58933-52-1

Usage

Uses

Used in Pharmaceutical Industry:
4-(BENZYLOXYCARBONYLAMINO-METHYL)-BENZOIC ACID is used as a key intermediate in the synthesis of paclitaxel-camptothecin conjugates for their antitumor properties. This application is crucial in the development of novel cancer treatments, as these conjugates have the potential to target and eliminate cancer cells more effectively than traditional chemotherapy drugs.
In the context of cancer research and drug development, 4-(BENZYLOXYCARBONYLAMINO-METHYL)-BENZOIC ACID plays a pivotal role in creating paclitaxel-camptothecin conjugates that can enhance the therapeutic efficacy and selectivity of cancer treatments. By participating in the synthesis of these conjugates, 4-(BENZYLOXYCARBONYLAMINO-METHYL)-BENZOIC ACID contributes to the advancement of cancer therapies and the improvement of patient outcomes.

Upstream product

• 56-91-7 p-aminomethylbenzoic acid 
• 501-53-1 benzyl chloroformate 
• 1885-14-9 phenyl chloroformate 

Downstream Products

• 82956-00-1 4-(Benzyloxycarbonylamino-methyl)-benzoic acid 6-carbamimidoyl-naphthalen-2-yl ester; compound with methanesulfonic acid 
• 162877-53-4 (S)-2-[4-(Benzyloxycarbonylamino-methyl)-benzoylamino]-pentanedioic acid di-tert-butyl ester 
• 851513-73-0 {[4-(benzyloxycarbonylamino-methyl)-benzoyl]-tert-butoxycarbonylmethyl-amino}-acetic acid tert-butyl ester 
• 560060-76-6 C₅₅H₅₈N₂O₁₅ 
• 63914-50-1 4-[[(phenylmethoxycarbonyl)amino]-methyl]benzenemethanamide 
• 1098022-32-2 3'-(N-benzyloxycarbonyl-4-aminomethylbenzoyl)amino-3'-deoxy-thymidine 
• 1257585-45-7 C₂₇H₃₆N₄O₅ 
• 1257585-46-8 C₁₉H₃₀N₄O₃ 
• 1257585-47-9 C₂₆H₃₄N₄O₆S 
• 1257585-48-0 C₂₅H₃₄N₆O₅S 
• 1257585-49-1 C₂₀H₂₆N₆O₃S 
• 1173158-65-0 N-methoxy-N-methyl(4-{[(phenylmethoxy)carbonylamino]methyl}phenyl)carboxamide 
• 1173156-38-1 2-{[2-({[N-({4-[2-((2R)-2-amino-3-(2-naphthyl)propanoylaminooxy)ethyl]phenyl}methyl)carbamoyl]methyl}{2-[bis(carboxymethyl)amino]ethyl}amino)ethyl](carboxymethyl)amino}acetic acid trifluoroacetic acid salt 
• 1173158-81-0 C₅₇H₈₆N₆O₁₃ 

Relevant academic research and scientific papers

A Red-Light-Activated Ruthenium-Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells

We describe two water-soluble ruthenium complexes, [1]Cl2 and [2]Cl2, that photodissociate to release a cytotoxic nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with a low dose (21 J cm?2) of red light in an oxyg

High-Fidelity End-Functionalization of Poly(ethylene glycol) Using Stable and Potent Carbamate Linkages

Commercial PEG-amine is of unreliable quality, and conventional PEG functionalization relies on esterification and etherification steps, suffering from incomplete conversion, harsh reaction conditions, and functional-group incompatibility. To solve these challenges, we propose an efficient strategy for PEG functionalization with carbamate linkages. By fine-tuning terminal amine basicity, stable and high-fidelity PEG-amine with carbamate linkage was obtained, as seen from the clean MALDI-TOF MS pattern. The carbamate strategy was further applied to the synthesis of high-fidelity multi-functionalized PEG with varying reactive groups. Compared to with an ester linkage, amphiphilic PEG-PS block copolymers bearing carbamate junction linkage exhibits preferential self-assembly tendency into vesicles. Moreover, nanoparticles of the latter demonstrate higher drug loading efficiency, encapsulation stability against enzymatic hydrolysis, and improved in vivo retention at the tumor region.

Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases

Tankyrases (TNKSs), members of the PARP (Poly(ADP-ribose)polymerases) superfamily of enzymes, have gained interest as therapeutic drug targets, especially as they are involved in the regulation of Wnt signalling. A series of 2-arylquinazolin-4-ones with varying substituents at the 8-position was synthesised. An 8-methyl group (compared to 8-H, 8-OMe, 8-OH), together with a 4′-hydrophobic or electron-withdrawing group, provided the most potency and selectivity towards TNKSs. Co-crystal structures of selected compounds with TNKS-2 revealed that the protein around the 8-position is more hydrophobic in TNKS-2 compared to PARP-1/2, rationalising the selectivity. The NAD+-binding site contains a hydrophobic cavity which accommodates the 2-aryl group; in TNKS-2, this has a tunnel to the exterior but the cavity is closed in PARP-1. 8-Methyl-2-(4-trifluoromethylphenyl)quinazolin-4-one was identified as a potent and selective inhibitor of TNKSs and Wnt signalling. This compound and analogues could serve as molecular probes to study proliferative signalling and for development of inhibitors of TNKSs as drugs.

SUBSTITUTED BENZAMIDES AND THEIR USES

Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.

Heteroarylacetic phenylbenzamide, composition and method of use (by machine translation)

Provided are certain heteroaryl benzamides, compositions, and methods of their manufacture and use.

ANTIMICROBIAL COMPOUNDS

The invention provides compounds for use in treating microbial infection in an animal. Example compounds include Pyridin-3-ylmethyl (4-((2-aminophenyl)- carbamoyl)benzyl)carbamate ("Entinostat"). The compounds can act via induction of the innate antimicrobial peptide defense system, and stimulation of autophagy.

SUBSTITUTED BENZAMIDES AND THEIR USES

Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.

Design and discovery of 2-arylquinazolin-4-ones as potent and selective inhibitors of tankyrases

Tankyrases (TNKSs) are poly(ADP-ribose)polymerases (PARPs) that are overexpressed in several clinical cancers. They regulate elongation of telomeres, regulate the Wnt system, and are essential for the function of the mitotic spindle. A set of 2-arylquinazolin-4-ones has been designed and identified as potent and selective TNKS inhibitors, some being more potent and selective than the lead inhibitor XAV939, with IC50 = 3 nM vs. TNKS-2. Methyl was preferred at the 8-position and modest bulk at the 4-position of the 2-phenyl group; electronic effects and H-bonding were irrelevant, but charge in the 4′-substituent must be avoided. Molecular modeling facilitated initial design of the compounds and rationalization of the SAR of binding into the nicotinamide-binding site of the target enzymes. These compounds have potential for further development into anticancer drugs.

HISTONE DEACETYLASE INHIBITORS AND USES THEREOF

The present invention discloses a group of histone deacetylase inhibitors and use thereof. The histone deacetylase inhibitors are useful in the treatment of malignant tumors and the diseases associated with differentiation and proliferation. The histone deacetylase inhibitors are the compounds represented by the following formula or salts thereof

Histone deacetylase inhibitors and uses thereof

The present invention discloses a group of histone deacetylase inhibitors and use thereof. The histone deacetylase inhibitors are useful in the treatment of malignant tumors and the diseases associated with differentiation and proliferation. The histone deacetylase inhibitors are the compounds represented by the following formula or salts thereof: